[go: up one dir, main page]

Yanagisawa et al., 2021 - Google Patents

Keto form of curcumin derivatives strongly binds to Aβ oligomers but not fibrils

Yanagisawa et al., 2021

View HTML
Document ID
11051675819454311914
Author
Yanagisawa D
Kato T
Taguchi H
Shirai N
Hirao K
Sogabe T
Tomiyama T
Gamo K
Hirahara Y
Kitada M
Tooyama I
Publication year
Publication venue
Biomaterials

External Links

Snippet

The accumulation of β-amyloid (Aβ) aggregates in the brain occurs early in the progression of Alzheimer's disease (AD), and non-fibrillar soluble Aβ oligomers are particularly neurotoxic. During binding to Aβ fibrils, curcumin, which can exist in an equilibrium state …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Yanagisawa et al. Keto form of curcumin derivatives strongly binds to Aβ oligomers but not fibrils
Williams et al. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Zhang et al. Neuroinflammation inhibition by small-molecule targeting USP7 noncatalytic domain for neurodegenerative disease therapy
Chen et al. Terazosin activates Pgk1 and Hsp90 to promote stress resistance
EP2282758B1 (en) Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
El Kadmiri et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease
EP2598882B1 (en) Safe and functional humanized antibodies for use in treating an amyloidosis
Irie New diagnostic method for Alzheimer’s disease based on the toxic conformation theory of amyloid β
Pedrero-Prieto et al. Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization
Si et al. Structure, distribution, and genetic profile of α-synuclein and their potential clinical application in Parkinson’s disease
JP2025142087A (en) Alpha-synuclein regulators
Yang et al. Amyloid‑β guided responsive theranostic fluorescent probe for imaging of endogenous hydrogen peroxide in Alzheimer disease
Chevalier et al. Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD
KR102716959B1 (en) Treatment of neurodegenerative disorders
US20180036433A1 (en) Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers
EP3273982B1 (en) Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
Park et al. Effects of Tau on the activity of triose phosphate isomerase (TPI) in brain cells
EP4140481A1 (en) Protein-oligomer binding agents and therapeutic uses thereof
Fukuzaki et al. Ovariectomy increases neuronal amyloid-β binding alcohol dehydrogenase level in the mouse hippocampus
Kim et al. Potential anti-amyloid beta oligomerization effects of PD166793 in Alzheimer's disease
US20210145801A1 (en) Therapy for protein misfolding disease
Herline Passive Immunization to Improve Cognition and Reduce Pathological Species in a Mouse Model of Alzheimer's Disease
Kim et al. Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease
Lee et al. Targeted degradation of pathologic tau aggregates via AUTOTAC ameliorates tauopathy
WO2025021697A1 (en) Trim21-binding molecules